Greg Simon, MD, MPH, is a psychiatrist and senior investigator well-known for his extensive research on practical approaches to improving mental health care. He seeks to develop and evaluate effective real-world strategies that support better mental health and wellness. Current areas of emphasis include identifying and assessing suicide risk, improving care for treatment-resistant depression, and reducing racial and ethnic disparities in mental health care.
Dr. Simon leads the Mental Health Research Network (MHRN), a consortium of research centers affiliated with 13 large health systems across the United States, including Kaiser Permanente Washington. This network, originally funded through a cooperative agreement with the National Institute of Mental Health, aims to improve the efficiency, relevance, and impact of mental health clinical and health services research. The MHRN is exploring a broad range of issues—including suicide prevention, improving heart health in people with serious mental illness, using electronic medical records to improve follow-up care for depression, and understanding the causes of racial and ethnic disparities in mental health care.
Dr. Simon and his MHRN colleagues have conducted several large studies across MHRN health systems, including:
Dr. Simon sits on the editorial board for the journal General Hospital Psychiatry, and co-chairs the National Academy of Medicine’s Forum on Drug Discovery, Development and Translation.. Dr. Simon has practiced adult psychiatry in Kaiser Permanente Washington's Mental Health and Wellness Service since 1990. He is also a professor in the department of Health Systems Science at the Bernard J Tyson Kaiser Permanente School of Medicine and an adjunct professor inPsychiatry and Behavioral Dciences at the University of Washington.
Depression; bipolar disorder; suicide prevention; self-management; treatment adherence
Comorbidity of mental health conditions with obesity, diabetes, heart disease, and substance use disorders.
Katon W, Von Korff M, Lin E, Simon G, Ludman E, Bush T, Walker E, Ciechanowski P, Rutter C. Improving primary care treatment of depression among patients with diabetes mellitus: the design of the Pathways study. Gen Hosp Psychiatry. 2003;25(3):158-68. PubMed
Araya R, Rojas G, Fritsch R, Gaete J, Rojas M, Simon G, Peters TJ. Treating depression in primary care in low-income women in Santiago, Chile: a randomised controlled trial. Lancet. 2003;361(9362):995-1000. PubMed
Unutzer J, Katon WJ, Russo J, Von Korff M, Lin E, Simon G, Walker E, Ludman E, Bush T. Willingness to pay for depression treatment in primary care. Psychiatr Serv. 2003;54(3):340-5. PubMed
Simon GE. Review: Low dose was as effective as standard dose tricyclic antidepressants in adults with depression. ACP J Club. 2003;138(2):52. PubMed
Sullivan MD, Russo J, Simon G, Spertus J. Depression and negative outcomes in patients with heart failure. Arch Intern Med. 2003 Feb 24;163(4):498; author reply 499. PubMed
Kessler RC, Barber C, Beck A, Berglund P, Cleary PD, McKenas D, Pronk N, Simon G, Stang P, Ustun TB, Wang P. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45(2):156-74. PubMed
Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res. 2003;12(1):22-33. PubMed
Simon GE, VonKorff M, Ludman EJ, Katon W, Rutter C, Unutzer J, Lin EHB, Bush T, Walker E. Cost-effectiveness of a program to prevent depression relapse in primary care. Med Care. 2002;40:941-50. PubMed
Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159(12):2055-61. PubMed
Simon GE. Review: Venlafaxine is more effective than selective serotonin-reuptake inhibitors for depression. ACP J Club. 2002;137(3):101. PubMed
In a new multistate study, the Zero Suicide Model reduced suicide rates by 25%.
Safety planning and risk screening improved outcomes for adult patients.
A new grant funds modeling work to make personalized treatment possible.
KPWHRI research finds ways to increase use of a firearm safety tool.
Study finds that many patients who might benefit from clozapine don’t receive it.